I serious doubt that.Look at the shareholder letter.Its clear funding was needed to complete the proof of concept with Lonza.
I maybe dead wrong but to me this was a good week.14 million shares most everything above the prior weeks close if you do not count the 15k at .135.
Someone accuried about 10 million this week IMO.Anything above .0131 was a positive to me.
LONZA is the key to the future regarding Intellect.OUR LEAD PROGRAM CONJUMAB!
Expect a great summer.How to File a Summary Judgment As a Plaintiff | eHow.com
Major media coverage sooner then later.
Have a great weekend.
Our lead program, CONJUMAB-A, offers an important advantage to the Aß antibodies currently in clinical development for both AD and AMD by several large pharmaceutical companies. This is because those antibodies (e.g. solanezumab, bapineuzumab, gantenerumab, crenzeumab, RN6G and GSK33766A) are designed for a single purpose, namely to clear Aß, while none act on the important secondary neurotoxic mechanisms, such as oxidative stress that causes most of the damage from Aß. By contrast, CONJUMAB-A is empowered with a potent antioxidant. An important step in establishing proof-of-principle was the initial data generated through our collaboration with iNovacia to evaluate compounds synthesized by Lonza for Intellect. The data demonstrated the conjugation of the antioxidant molecule to an amino acid does not reduce its antioxidant activity. (Pending adequate financial resources, these studies, which are almost complete, will allow us to select a drug candidate to take into development, providing the trigger for us to move forward with LONZA into an expanded manufacturing project, bringing us closer to the submission of an Investigational New Drug application).
News 
Market Data 
Discover 
AI
